AquaBounty Facing Environmental Complaint in Panama
By admin,
The Guardian
| 11. 23. 2013
A U.S. company with a Prince Edward Island research facility is facing a complaint in Panama alleging that it is in breach of the country’s environmental regulations.
The Environmental Advocacy Center of Panama submitted a complaint to the country’s National Environmental Authority earlier this week alleging that AquaBounty’s research and development of Genetically Modified (GM) Atlantic salmon is in breach of environmental regulations.
The company produces salmon eggs in P.E.I., which are then shipped to Panama for further research and development.
Sharon Labchuk, of the P.E.I. group “Islanders Say No to Frankenfish”, said she was surprised at the complaint.
“We always assume that because something is as controversial as this is, the proper controls are in place,” said Labchuk. “It’s also very experimental and the risks of anything going wrong are disastrous. They can wipe out the wild salmon population if these fish ever escape and their eggs end up in the wild rivers.”
The National Environmental Authority in Panama conducted an inspection of the AquaBounty operation in 2012 and allegedly found violations that remained uncorrected by the company. Those...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...
